<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0360">
 <label>72</label>
 <element-citation publication-type="journal" id="rf0355">
  <person-group person-group-type="author">
   <name>
    <surname>Biggioggero</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Becciolini</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Crotti</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Agape</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Favalli</surname>
    <given-names>E.G.</given-names>
   </name>
  </person-group>
  <article-title>Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis</article-title>
  <source>Drugs Context</source>
  <volume>8</volume>
  <year>2019</year>
  <fpage>212595</fpage>
  <pub-id pub-id-type="doi">10.7573/dic.212595</pub-id>
  <pub-id pub-id-type="pmid">31692920</pub-id>
 </element-citation>
</ref>
